ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
Aim. To analyze the structure of expenses associated with warfarin dose adjustment and international normalized ratio (INR) control for patients with atrial fibrillation (AF) per 1 year of treatment. Material and methods. AF prevalence rate was calculated according to the large population studies da...
Main Authors: | Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2016-01-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/899 |
Similar Items
-
The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01) -
PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01) -
Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
by: Krishna N. Pundi, et al.
Published: (2021-12-01) -
COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
by: L. E. Kuvshinova, et al.
Published: (2015-09-01) -
Cost effectiveness of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients in Saudi Arabia: A Single–Center retrospective cohort study
by: Yazed AlRuthia, et al.
Published: (2023-01-01)